Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Overview
Organogenesis Holdings Inc (ORGO) is a global, innovative force in the field of regenerative medicine, specializing in the development, manufacture, and commercialization of bioactive and acellular biomaterials. With a robust portfolio that spans advanced wound care, surgical biologics, and targeted sports medicine solutions, the company addresses complex repair and regenerative needs across various patient segments. By integrating advanced technologies and scientific research, Organogenesis delivers products that enhance tissue regeneration, promote wound healing, and provide surgical support in orthopedics and spine applications.
Core Business and Product Portfolio
At the heart of Organogenesis Holdings Inc is its commitment to regenerative medicine. The company’s dual-segment business model emphasizes a comprehensive range of products designed for advanced wound care and surgical applications. Among its offerings are bioactive skin substitutes, acellular matrices, and innovative surgical barriers that provide clinicians with non-surgical and surgical options for managing complex wounds and soft tissue injuries. The scientifically backed formulation of these products underscores a deep understanding of tissue repair mechanisms and exemplifies the integration of clinical research with manufacturing excellence.
Market Position and Industry Expertise
Operating within a highly specialized niche in healthcare, Organogenesis stands as a testament to applied research and technical innovation in regenerative medicine. The company’s products are designed to address longstanding clinical needs, offering alternatives where traditional therapies have limitations. With significant emphasis on data-driven outcomes and safety profiles, their approach reassures stakeholders and medical professionals alike. Their market presence is reinforced by the clinical validation of key product categories, strategic manufacturing locations, and a commitment to scalable, high-quality production practices.
Regulatory and Clinical Integration
Organogenesis navigates a complex regulatory landscape that governs the development of medical products. Their adherence to stringent clinical protocols and transparent reporting standards reflects in the rigorous evaluation of their products in clinical trials. This commitment not only bolsters trust within the scientific community but also demonstrates a sustainable model based on continuous innovation and quality assurance. The company’s efforts in seeking clinical validation and integrating regulatory feedback highlight their operational expertise in transforming scientific discoveries into reliable therapeutic applications.
Why Investors and Analysts Watch Organogenesis
Investors and market analysts recognize Organogenesis not only for its diverse product lineup but also for its strong foundation rooted in regenerative medicine expertise. The company’s operational strategies, which blend scientific research with advanced manufacturing, serve as a model of precision and innovation in a competitive healthcare environment. Detailed insights into their product efficacy, market positioning, and tailored solutions for unmet clinical needs provide a clear window into the operational dynamics and the strategic value proposition of Organogenesis Holdings Inc.
Conclusion
The comprehensive approach of Organogenesis in addressing advanced wound care and surgical challenges is supported by decades of applied research in regenerative medicine. By focusing on bioactive and acellular biomaterials, the company continues to underpin its reputation as a trusted innovator, providing diversified yet focused solutions that cater to a wide array of clinical needs. The structured integration of scientific research, clinical trials, and manufacturing excellence makes Organogenesis an informative case study in modern patient care and biomedical innovation.
Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.
For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.
For 2025 guidance, Organogenesis expects:
- Net revenue between $480.0-$535.0 million
- Net income between $9.5-$38.8 million
- Adjusted EBITDA between $43.6-$83.2 million
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.
Organogenesis Holdings (Nasdaq: ORGO) welcomes the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts and cellular tissue-based products treating diabetic foot ulcers and venous leg ulcers. The LCD, effective February 12, 2025, is based on peer-reviewed clinical efficacy data. Organogenesis offers 4 products for diabetic foot ulcers, including NuShield, and 2 for venous leg ulcers. The company's NuShield product has been added to the list of covered products, marking a positive development for both the company and industry.
Organogenesis Holdings (NASDAQ: ORGO) reported Q3 2024 financial results with net revenue of $115.2 million, up 6% from Q3 2023. Advanced Wound Care revenue increased 7% to $108.0 million, while Surgical & Sports Medicine revenue grew 1% to $7.2 million. Net income reached $12.3 million ($0.09 per share), up from $3.2 million in Q3 2023. Adjusted EBITDA was $13.4 million, down from $16.0 million year-over-year. The company updated its FY2024 guidance, expecting net revenue between $455-480 million, representing 5-11% growth, with projected net loss between $12.3-0.6 million.
Organogenesis Holdings (Nasdaq: ORGO) has secured a $130 million private placement through the sale of Series A Convertible Preferred Stock to Avista Healthcare Partners. The net proceeds will fund strategic growth initiatives, including operating activities, clinical development, working capital, and debt repayment. $23.5 million will be used to repurchase 7.4 million shares of common stock from certain directors. The Preferred Stock is convertible into common stock at $3.79 per share, a 20% premium to recent trading. Investors will receive an 8% annual dividend, and Garrett Lustig from Avista joins the Board of Directors.
Organogenesis Holdings (ORGO) announced positive interim analysis results from its second Phase 3 clinical trial of ReNu for knee osteoarthritis treatment. The analysis, covering 50% of 474 planned patients with moderate to severe knee OA, focused on the 6-month primary endpoint. The independent Data Monitoring Committee recommended proceeding without modifications or sample size increases, confirming favorable results and consistent safety profile. The fully enrolled 594-patient trial is evaluating ReNu versus saline control through intra-articular injection, with the primary endpoint measuring knee pain reduction using the WOMAC pain scale. Knee OA affects nearly 31.1 million Americans, projected to reach 34.4 million by 2027.
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, has announced that it will report its third quarter fiscal year 2024 financial results after the market closes on Tuesday, November 12th, 2024. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the quarterly results and provide a corporate update, followed by a question and answer session.
Interested parties can access the live webcast through the company's website at investors.organogenesis.com or via a provided link. A teleconference option is also available. The webcast will be archived on the company's website for approximately one year after the event.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced the publication of a randomized clinical trial (RCT) demonstrating the safety and efficacy of NuShield for diabetic foot ulcers (DFUs). The study, published in the Journal of Wound Care, involved 218 patients with Wagner 1 or 2 grade DFUs.
Key findings include:
- NuShield showed statistically superior frequency of wound closure (p=0.04) compared to standard of care (SoC) at weeks 4, 6, 8, 10, and 12
- The NuShield group demonstrated a 48% greater probability of wound closure and decreased median time to complete wound closure
Organogenesis believes this study satisfies requirements for Medicare coverage under proposed Local Coverage Determination (LCDs).
Organogenesis Holdings (Nasdaq: ORGO), a leading regenerative medicine company, has announced its participation in two upcoming investor conferences in September 2024. The company will attend:
1. The Morgan Stanley Global Healthcare Conference in New York, NY, where management will participate in investor 1x1 meetings without a formal presentation.
2. The Cantor Fitzgerald Global Healthcare Conference in New York, NY, featuring a fireside chat on September 18 at 1:20 p.m. Eastern Time. This presentation will be webcast and accessible via the company's website, with a replay available for approximately 30 days.
These conferences provide Organogenesis an opportunity to showcase its focus on developing, manufacturing, and commercializing product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
What is Organogenesis Holdings Inc?
Which markets does the company serve?
What types of products does Organogenesis offer?
How does Organogenesis ensure the quality of its products?
What is the core focus of Organogenesis in regenerative medicine?
How is Organogenesis positioned within the healthcare industry?
How does the company integrate clinical research into its product development?
